Lexaria Bioscience Corp. (LEXXW)

NASDAQ: LEXXW · Real-Time Price · USD · Warrants

0.0012

-0.0041 (-77.36%)

At close: Jan 13, 2026

Market Cap	5.09M -78.8%
Revenue (ttm)	194,000 -30.0%
Net Income	-7.73M
EPS	-5.14
Shares Out	1.65M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	283,190
Open	0.0009
Previous Close	0.0053
Day's Range	0.0009 - 0.0045
52-Week Range	0.0009 - 0.8000
Beta	0.52
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 27, 2026

About LEXXW

Lexaria Bioscience Corp. operates as a biotechnology company. The company offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods. Its DehydraTECH is used with a range of active molecules, including ... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2004

Employees 7

Stock Exchange Nasdaq

Ticker Symbol LEXXW

Website https://lexariabioscience.com

Full Company Profile

News

Lexaria Bioscience reaches full enrollment in GLP-1-H26-7 study

Lexaria Bioscience (LEXX) reports that full enrollment has been reached and dosing continues on schedule with Human Pilot Study #7 which is evaluating two oral DehydraTECH-semaglutide compositions aga...

4 days ago - TheFly

Lexaria's Human Study GLP-1-H26-7 Reaches Full Enrollment and Continues Dosing on Schedule

Kelowna, BC – October 21, 2026 – TheNewswire - Lexaria Bioscience Corp. (NASDAQ:LEXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, reports that full enrollment has been...

4 days ago - TheNewswire

Lexaria Bioscience announces results from animal study GLP-1-A26-1

Lexaria Bioscience (LEXX) provides the following results from animal study GLP-1-A26-1 that evaluated a number of formulation enhancements using both DehydraTECH-CBD compositions and DehydraTECH-semag...

10 days ago - TheFly

Lexaria Announces Results from Animal Study GLP-1-A26-1

Results highlighted by a 566% improvement in brain absorption of DehydraTECH-CBD KELOWNA, BC / ACCESS Newswire / October 15, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"),...

10 days ago - Accesswire

Lexaria Announces Results From Animal Study GLP-1-A26-1

Results highlighted by a 566% improvement in brain absorption of DehydraTECH-CBD Kelowna, BC – October 15, 2026 – TheNewswire - Lexaria Bioscience Corp. (NASDAQ:LEXX) (the “Company” or “Lexaria”), ...

10 days ago - TheNewswire

GLP-1 Weight-Loss/Diabetes Industries Continue Transition to Oral Medications

Oral GLP-1 market projected to expand from $5.1 billion in 2026 to $89 billion in 2034 Novo announces additional weight-loss in patients switching from injected to oral delivery KELOWNA, BC / ACCESS N...

19 days ago - Accesswire

Lexaria Bioscience Registration statement: Registration filing

Lexaria Bioscience filed a registration statement on October 2, 2026, providing details about a securities offering with the SEC.

23 days ago - Filings

Lexaria Bioscience files to sell 923,827 shares of common stock for holders

This filing relates to the offer and sale from time to time by the selling stockholders of up to 923,827 shares of common stock. The company is not selling any…

23 days ago - TheFly

Lexaria Bioscience updates financial position

Lexaria Bioscience (LEXX) said it is in a strong cash position following both its recently announced Australian tax refund and recent institutional financing priced at $12.92/share. The combined net p...

5 weeks ago - TheFly

Lexaria Updates Financial Position

Kelowna, British Columbia – September 17, 2026 - TheNewswire - Lexaria Bioscience Corp. (NASDAQ:LEXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms is providing the follo...

5 weeks ago - TheNewswire

Lexaria Announces Closing of Exercise of Warrants For Approximately $5.9 Million in Gross Proceeds

Kelowna, British Columbia – September 9, 2026 – TheNewswire - Lexaria Bioscience Corp. (NASDAQ:LEXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, today closed its previ...

6 weeks ago - TheNewswire

Lexaria Announces Closing of Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds

KELOWNA, BC / ACCESS Newswire / September 9, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today closed its previously anno...

6 weeks ago - Accesswire

Lexaria Bioscience announces exercise of warrants for $5.9M in proceeds

Lexaria Bioscience (LEXX)s announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase an aggregate of 453,969 shares of the Company’s common ...

6 weeks ago - TheFly

Lexaria Announces Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds

KELOWNA, BC / ACCESS Newswire / September 8, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced th...

6 weeks ago - Accesswire

Lexaria Announces Exercise of Warrants For Approximately $5.9 Million in Gross Proceeds

Kelowna, British Columbia – TheNewswire - September 8 , 2026 - Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, today announce...

6 weeks ago - TheNewswire

Lexaria to Present at the H.C. Wainwright 28th Annual Global Investment Conference

KELOWNA, BC / ACCESS Newswire / September 4, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, announces that it will part...

7 weeks ago - Accesswire

Lexaria Bioscience receives $2.6M tax rebate payment

Lexaria Bioscience (LEXX) has received a cash rebate of AUD$3,666,611.98 from the Australian Tax Office. The funds were deposited into the bank account of Lexaria’s wholly-owned Australian subsidiary ...

7 weeks ago - TheFly

Lexaria Receives USD$2.6 Million Tax Rebate Payment

Lexaria's 2025 Australian human study results in a USD$2.6 million cash rebate KELOWNA, BC / ACCESS Newswire / September 1, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), ...